Fierce Pharma
NOVEMBER 4, 2024
BioNTech reported surprisingly strong sales of its COVID-1 | BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter. Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2.5 billion to €3.1 billion.
MedCity News
NOVEMBER 4, 2024
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The post Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 4, 2024
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and | Sun Pharma, which had been plotting a mid-October launch for its JAK inhibitor Leqselvi, has been slapped with in an injunction blocking the rollout of the alopecia areata drug.
MedCity News
NOVEMBER 4, 2024
Jason Hill, Ochsner Health’s innovation officer, said he goes to sleep most nights and wakes up most morning worried about one thing: the state of generative AI governance in healthcare. To him, providers and other healthcare organizations are in dire need of frameworks to ensure their AI tools are safe and perform well over time. The post Why AI Governance Is the Number 1 Issue on This Health System Exec’s Mind appeared first on MedCity News.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
NOVEMBER 4, 2024
As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against competitors.
MedCity News
NOVEMBER 4, 2024
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing. The post Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 4, 2024
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction. The post A Recipe for Better Obesity Care: Integrating GLP-1s with Food as Medicine appeared first on MedCity News.
Fierce Pharma
NOVEMBER 4, 2024
Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over Galderma's standard-of-care Oracea capsules in phase 3 studies, leaving Journey to deploy its dermatology sales force to establish Emrosi as a dominant treatment.
pharmaphorum
NOVEMBER 4, 2024
Accord Healthcare unveils £50m investment, backed by the UK government, that will see a new manufacturing facility built in Newcastle
MedCity News
NOVEMBER 4, 2024
Steps that healthcare providers can take – internally and with the help of external partners – to boost both their security capabilities and the confidence of their clinicians in those capabilities The post Imaging Practices Can Restore Their Clinicians’ Cybersecurity Confidence With These Four Steps appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
pharmaphorum
NOVEMBER 4, 2024
Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD
MedCity News
NOVEMBER 4, 2024
I met a mix of biotech and healthtech companies at HLTH affecting everything from drug development, drug efficacy to controlling specialty care costs and managing chronic diseases. The post 5 Interesting Companies I Saw at HLTH appeared first on MedCity News.
Pharmaceutical Technology
NOVEMBER 4, 2024
Researchers from Northwestern and Case Western Reserve universities have developed a polymer therapeutic to treat Huntington's disease.
pharmaphorum
NOVEMBER 4, 2024
NHS England starts pilot trial of an iPhone app and device that could be used by nurses to speed up reviews of suspected throat cancer cases.
Pharmaceutical Technology
NOVEMBER 4, 2024
The US FDA has granted fast track designation to FELIQS’ lead product FLQ-101 for preventing retinopathy of prematurity (ROP).
MedCity News
NOVEMBER 4, 2024
There are some areas where point solutions make a lot of sense, such as when they’re focused on a condition without a lot of comorbidities, according to one healthcare expert. The post Is There Still a Place for Point Solutions? One Investor Weighs In appeared first on MedCity News.
pharmaphorum
NOVEMBER 4, 2024
US district court grants an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata
PharmaTech
NOVEMBER 4, 2024
This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism of mucoadhesion and methods to evaluate it in the context of pharmaceutical applications will also be reviewed, also how it can improve and differentiate drug products.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
NOVEMBER 4, 2024
Novo Nordisk puts $285m into a once-monthly GLP-1 agonist for obesity using technology developed by fellow Danish pharma Ascendis
PharmaTech
NOVEMBER 4, 2024
Carbopol® polymers are efficient suspending agents that simplify manufacturing and improve the dosing experience for pediatric and geriatric patients. They offer excellent performance and versatility as pharmaceutical suspending agents for oral liquid formulations. They are compatible with various APIs, flavors, and preservatives and also provide a reliable supply.
PharmExec
NOVEMBER 4, 2024
Results from the VENTURE Phase II trial and a Phase I oral formulation study found that VK2735, a novel a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.
PharmaTech
NOVEMBER 4, 2024
Looking to improve drug product effectiveness and differentiate? Mucoadhesion – the ability of a formulation to adhere to a mucous membrane – is an attractive option for those keen to ensure their products stand out in a crowded market.
European Pharmaceutical Review
NOVEMBER 4, 2024
The final text of Chapter <86> Bacterial Endotoxins Test Using Recombinant Reagents has been published for early option, according to US Pharmacopeia (USP). The chapter covers endotoxin testing using non-animal derived reagents and is set to become official in May 2025, the organisation announced. Further techniques for bacterial endotoxin testing (BET) using these alternative reagents, such as recombinant cascade (rCR) and recombinant Factor C (rFC) reagents, are included in Chapter
Pharmaceutical Commerce
NOVEMBER 4, 2024
In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, explains why ultra-precise temperature control and customized logistics solutions are critical when it comes to biologics and personalized medicine.
PharmExec
NOVEMBER 4, 2024
Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explores the most promising alternative targeting methods that advertisers can adopt in a post-cookie world, and how they compare to traditional approaches.
Pharmaceutical Commerce
NOVEMBER 4, 2024
With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
NOVEMBER 4, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
NOVEMBER 4, 2024
Increasingly, injectable manufacturers recognise that to achieve maximum profitability, they need to focus on the value they provide.
PharmaVoice
NOVEMBER 4, 2024
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
Pharmaceutical Technology
NOVEMBER 4, 2024
UK-based biopharmaceutical company Prokarium has received two Notices of Allowance from the US Patent and Trademark Office.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
270 
Let's personalize your content